Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10720723 | 0.93 | HSD17B10 (0.68) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL842621 | 0.92 | HSD17B10 (0.70) | SMYD2KMT2AMEN1HPGDHSD17B10 | |
| SCHEMBL280088 | 0.91 | HSD17B10 (0.72) | SMYD2KMT2AMEN1HPGDHSD17B10 | |
| SCHEMBL178368 | 0.90 | HSD17B10 (0.64) | SMYD2KMT2AMEN1HSD17B10MAPT | |
| SCHEMBL10192030 | 0.88 | ALDH1A1 (0.70) | HSD17B10POLB | |
| SCHEMBL5476524 | 0.85 | SMYD2 (0.62) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL5487158 | 0.85 | SMYD2 (0.62) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL16964662 | 0.85 | MAPT (0.62) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL5474859 | 0.85 | MEN1 (0.61) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL14430686 | 0.84 | DRD4 (0.70) | SMYD2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | GRIN2C, TPH2, HTR5A | SMYD2 805/4885KMT2A 234/4885MEN1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.